Method for treating allergic conditions

• US 4,804,678 A
• Filed: 10/05/1987
• Issued: 02/14/1989
• Est. Priority Date: 01/22/1982
• Status: Expired due to Fees

• Current Assignee: Fisons PLC (Sanofi )
• Original Assignee: Fisons PLC (Sanofi )
• Inventors: Augstein, Joachim, Ahmed, Maqbool
• Primary Examiner(s): Rosen, Sam
• Application Number:
  US07/105,508
• Time in Patent Office: 498 Days
• Field of Search: 424/45, 424/450, 424/DIG. 7, 514/460, 514/456, 428/402.2
• US Class Current: 514/456
• CPC Class Codes: A61K 31/35 having six-membered rings with one oxygen as the only ring hetero atom
• CPC Class Codes: A61K 9/127 Liposomes

Abstract

There is described a pharmaceutical composition comprising liposomes and sodium cromoglycate.

There is also described an aqueous suspension comprising sodium cromoglycate partitioned between a free aqueous phase and a liposome phase.

There is further described a method for making the compositions, and their use in the treatment of allergic conditions, e.g., asthma.

Claims

1. A method of treatment of an allergic condition which comprises administration by inhalation of an aqueous suspension in a free aqueous phase of liposomes containing sodium cromoglycate said suspension comprising an effective amount of sodium cromoglycate partitioned between said free aqueous phase and said liposomes to a patient suffering from said condition.

2. A method in accordance with claim 1 wherein said liposomes have diameters between 100 nm and 100 μ

m.

3. A method in accordance with claim 1 wherein said liposomes comprise one or more natural or synthetic lecithins.

4. A method in accordance with claim 3 wherein said composition further includes a component having a negative or positive charge.

5. A method in accordance with claim 3 wherein said lecithins have a phase transition temperature in the range of 35°

-45°

C.

6. A method in accordance with claim 5 wherein said liposomes contain at least one additional component selected from the group consisting of cholesterol and cholesterol stearate.

7. A method in accordance with claim 1 wherein said liposomes comprise a lipid and sodium cromoglycate in a ratio by weight of sodium cromoglycate to lipid of 0.01 to 100.

8. A method in accordance with claim 1 wherein the total concentration of sodium cromoglycate in said suspension is from 0.01 to 50 mg/ml.

9. A method in accordance with claim 1 wherein the concentration of sodium cromoglycate in said suspension is 2-35% by weight.

10. A method in accordance with claim 1 wherein said suspension comprises 0.1 to 20 mg/ml of sodium cromoglycate and said liposome phase comprises at least one of the lecithins di-(tetradecanoyl)phosphatidylcholine, di((hexadecanoyl)phosphatidylcholine and di-(octadecanoyl) phosphatidylcholine, the concentration of lecithins dispersed in the aqueous phase is from 1 to 30 mg/ml and the percentage of sodium cromoglycate associated with the liposomes is from 2 to 35% w/w.